Replies to post #46141 on Cytodyn Inc (CYDY)

[XeoX_X]

From a technical standpoint, bottom should be in, I wonder if this may see a nice bounce here soon and can be traded at these levels and flipped.

Will be watching.

[plavac]

I have not seen any company where this went smoothly and without delay. Some attack CYDY saying it's a scam. Yesterday, Yale University announced ten diseases that can be treated with CCR5 antagonists, every day someone writes about CCR5, they can't all be wrong. Leronlimab has been tested in over 830 patients without any serious side effects and has proven effective in blocking CCR5. Something that showed a high + 98% activity in mice, if it's half the value in humans, it's worth billions, and then if it works in most metastases where the CCR5 receptor occurs then this is a worldwide blockbuster. NP does not want to sell Leronlimab for 10% royalties and I support it.

[lorbas95]

I think you have some good points.

While the FDA communicates that they want this adamantly approved, their actions speak differently, and they give their best to troll CYDY as hard as possible. Would it be better, if someone else was in charge? Who knows? Perhaps if we got a super-muscular ex-Gilead nobel-prize winning CEO that intimidated FDA reviewers by his mere presence, lol. We've got a good relationship with FDA insofar as the cancer and GvHD studies are approved rapidly and insofar as they didn't require 100 patients for combo trial etc.

Further, there is no excuse for not having the 700mg stability data ready by now, which delays BLA submission for 1 or even 1,5 months. This costs another 7.5m roughly, money CYDY does not have at this point. Moreover, it seems clear that Nader did not watch Pestell closely enough, which cost us dearly (quite understandable though - who could have suspected such a mess?).

And I agree that he shouldn't have had a bonus - not until we are OVER the finish line and SP reflects the progress. But shareholders approved it, and so be it.

At this point, we simply have to wait another five weeks to see whether the deal comes to fruition.

And let's not forget that Nader saved leronlimab from being shelved and failing (which is a huge achievent and many future patients will owe him their lives for this).